stifel - Search News

Stifel, Cytokinetics

Cytokinetics started at buy by Stifel, aficamten highlighted

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming catalysts. Read more here.

Business Insider · 1d

Cytokinetics initiated with a Buy at Stifel

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the

Fintel on MSN · 9h

Stifel Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation. Analyst Price Forecast Suggests 85.04% Upside As of December 23, 2024, the average one-year price target for Cytokinetics is $84.

Investing.com on MSN · 23h

Stifel starts Cytokinetics stock with Buy, $80 target

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of $80.00. The new coverage comes after a period of instability for the company,

Stifel Financial Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market opens on Wednesday, January 29, 2025. The company will host a conference call ...

Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Hosted on MSN2h

Deregulation will help growth and tap down inflation, Stifel CEO says

Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates ...

4hon MSN

Stifel maintains Buy on Revolve stock with $41 target

Stifel analysts kept a Buy rating on Revolve Group (NYSE:RVLV) shares, maintaining a $41.00 price target. The firm is ...

Canada’s Eight Capital to Shut Down as Stifel Swoops In for Bankers

Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.

Fastenal price target lowered to $82 from $86 at Stifel

Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...

Edgewise Therapeutics initiated with a Hold at Stifel

Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...

24/7 Wall St1d

2025 Bull Market: Here's How High These Wall Street Analysts Think the Market Could Go In 2025

Wall Street analysts are buzzing with optimism as we step into 2025. There are plenty of reasons for a positive view to ...

bovnews1d

Why Did Stifel Give Altimmune Inc (ALT) Stock Buy Rating?

Altimmune Inc (ALT) stock saw a modest uptick, ending the day at $6.86 which represents a slight increase of $0.15 or 2.24% from the prior close of $6.71. The stock opened at $6.8 and touched a low of ...